Leo Pharma plans to acquire dermatology biotech Timber Pharmaceuticals, which is developing a treatment for a rare, genetic skin disease. The privately held Danish biopharma
Republican presidential candidate and former biotech CEO Vivek Ramaswamy, and the anti-ESG asset management company he co-founded, were sued in recent months by two former
The FDA put a partial clinical hold on Gilead’s magrolimab for acute myeloid leukemia, a month after the company scrapped late-stage development of the CD47
Skye Bioscience acquired Bird Rock Bio to get its hands on an asset targeting CB1 just two weeks after Novo Nordisk dipped its toes into
In a field full of eccentrics, Jacob Kimmel may stand out most for his normality. Kimmel is a leading anti-aging researcher who isn’t trying to
Genesis Therapeutics, a startup using artificial intelligence to design small molecule drugs, has raised $200 million in Series B financing — one of the largest
After Mark McKenna sold a biotech for $10.8 billion, the executive recruiters likely came knocking, trying to poach the CEO who took an immunology and
CARsgen will test its Claudin18.2 CAR T-cell candidate, dubbed CT041, in combination with Moderna’s investigational mRNA cancer vaccine in a collaboration between the two companies.
Healthcare facilities should reconsider their approaches to masking, a group of public health experts argued. “As health care systems navigate this next phase of the
Three-quarters of the highest-revenue patient advocacy organizations (PAOs) in the U.S. have board members or senior leadership with ties to the pharmaceutical or medical device